Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Given's PillCam gets Italian reimbursement boost:

This article was originally published in Clinica

Executive Summary

Given Imaging has secured wider access for its PillCam endoscopy "video pill" in Europe, with the approval of its reimbursement in Italy's Piedmont region. The decision supports the use of the technology - until recently known as M2A - as an outpatient procedure in the treatment of a number of small bowel disorders, including Crohn's disease, coeliac disease, lymphoma, polyposis and occult bleeding. The Yoqneam, Israel-based specialist in capsule endoscopy claims that the approval by the regional government of Piedmont, with 4.3 million people, extends PillCam's reimbursement coverage to an EU-wide population of around 44 million. Given Imaging rebranded the M2A video capsule as PillCam on September 9 (see Clinica No 1124, p 17).

You may also be interested in...

WHO No-Go Not A Swan Song For Remdesivir In India?

The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things. 

QUOTED. 30 November 2020. David Hoffmeister.

A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts